Dr. Koehler brings over 20 years of oncology drug development leadership experience to Remix's Board of Directors WATERTOWN, Mass., June 18, 2024 /PRNewswire/ -- Remix Therapeutics (Remix), a clinical ...
The Remix management team will also be hosting one-on-one meetings with investors. For those investors interested in scheduling a meeting, please contact your Guggenheim representative. Remix ...
"The preclinical data for REM-422 provide strong therapeutic rationale for our ongoing Phase I study in AML and High-Risk MDS," said Peter Smith, Ph.D., President and Chief Executive Officer of Remix ...
Remix Therapeutics said it received positive preliminary results for the ongoing Phase 1 of its lead drug, REM-422, in treating adenoid cystic carcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback